TICKERNERD
Menu
CLDXCLDXHealthcare · Biotechnology

CLDX Stock Forecast: Celldex Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$40
+1.18% on the day

The 16 Wall Street analysts covering Celldex Therapeutics, Inc. hold a median 12-month price target of $56 — +38.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.2B
Ticker Nerd rank
31 / 100
Median analyst target
$56
Analysts covering
16
Total return, dividends reinvested
1W
−3.7%
1M
+13.3%
YTD
+48.8%
1Y
+83.5%
From 52W high
−9.9%
From 52W low
+85.8%
$22
$45
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CLDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Celldex Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
87
Revisions
69
Accruals
67
Volatility
45
Size
30
Issuance
28
Growth
27
Quality
16
Value
15

Momentum (87): The shares have been drifting up relative to others.

Value (15): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100Oct 25Jan 26Apr 26Jul 26CLDXHigh $100Median $56Low $38

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says16 analysts
15 Buy1 Hold0 Sell
Low $38Median $56High $100

The green dot is the last close — the median target sits +38.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
7 Aug 2026BarclaysMaintainsOverweight$48 → $53
7 Aug 2026Morgan StanleyMaintainsOverweight$40 → $46
29 July 2026Wells FargoMaintainsOverweight—
29 July 2026Wells FargoMaintainsOverweight$48 → $72
22 July 2026Canaccord GenuityMaintainsBuy—
22 July 2026Canaccord GenuityMaintainsBuy$62 → $60
22 July 2026Cantor FitzgeraldMaintainsOverweight$67 → $61
22 July 2026Cantor FitzgeraldMaintainsOverweight—
22 July 2026Morgan StanleyMaintainsOverweight$44 → $40
22 July 2026Morgan StanleyMaintainsOverweight—
22 July 2026Wells FargoMaintainsOverweight$54 → $48
22 July 2026Wells FargoMaintainsOverweight—
20 July 2026GuggenheimMaintainsBuy—
20 July 2026GuggenheimMaintainsBuy$90 → $100
15 June 2026HC Wainwright & Co.ReiteratesBuy$42
15 June 2026HC Wainwright & Co.ReiteratesBuy—
10 June 2026UBSMaintainsBuy$38 → $45
10 June 2026UBSMaintainsBuy—
13 May 2026Wells FargoMaintainsOverweight—
8 May 2026BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLDX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CLDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

Celldex Therapeutics, Inc. (CLDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.4×

Cheaper than 93% of US stocks

Price / sales
20069.8×

Cheaper than 1% of US stocks

Price / book
4.4×

Cheaper than 25% of US stocks

EV / EBITDA
−7.6×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
−97.0%

Higher than 2% of US stocks

Earnings growth (YoY)
−97.0%

Higher than 2% of US stocks

Gross margin
—
Operating margin
−366468.2%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−43.9%

Higher than 23% of US stocks

Return on assets
−27.6%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CLDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CLDXCelldex Therapeutics, Inc.$3.2B
31
ARQTArcutis Biotherapeutics, Inc.$3.1B
88
TARSTarsus Pharmaceuticals, Inc.$3.1B
84
SLSSELLAS Life Sciences Group, Inc.$3.1B
65
ALMSAlumis, Inc.$3.1B
51
IMNMImmunome, Inc.$3.1B
33
MBXMBX Biosciences, Inc.$3.2B
35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Celldex Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLDX news & analysis

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 7 Aug 2026negative

Celldex Therapeutics reported a second-quarter loss of $0.94 per share, which was narrower than the Zacks Consensus Estimate of a $1.04 loss but wider than the $0.85 per-share loss from a year ago. The company missed revenue estimates for the quarter.

Why it matters — The quarter's results fall short of revenue expectations and show a year-over-year deterioration in per-share losses, which CLDX watchers monitoring the company's financial trajectory would want to track.

Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts

Seeking Alpha · 26 July 2026positive

Celldex Therapeutics' barzolvolimab phase 3 trials for chronic spontaneous urticaria completed enrollment six months early, with pivotal data expected in September/October 2026 and a potential BLA filing in 2027. The company is also advancing CDX-622, a bispecific TSLP & SCF inhibitor targeting asthma and inflammatory disorders.

Why it matters — The accelerated enrollment timeline for barzolvolimab's phase 3 trials moves Celldex's most advanced candidate closer to a potential regulatory filing, while the early-phase progress of CDX-622 expands the company's pipeline beyond CSU into additional inflammatory indications.

Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?

Zacks Investment Research · 24 July 2026neutral

A Zacks Investment Research article compares the year-to-date performance of Celldex Therapeutics (CLDX) to Illumina (ILMN) and their broader medical sector.

Why it matters — CLDX watchers would care because the article offers a relative performance benchmark against both a peer company and the medical sector as a whole.

FAQ

Frequently asked questions about CLDX stock

What is the CLDX stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Celldex Therapeutics, Inc. have a median 12-month price target of $56, with estimates ranging from $38 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CLDX stock a buy right now?

Of the 16 analysts covering Celldex Therapeutics, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Celldex Therapeutics, Inc. 31 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLDX?

As at 22 Aug 2026, Celldex Therapeutics, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (87 of 100).

Will CLDX stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +38.6% from the last close, and Ticker Nerd's factor model ranks Celldex Therapeutics, Inc. 31 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CLDX stock forecast for 2030?

No analyst covering Celldex Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $100 over the next 12 months.

How has CLDX stock performed over the past year?

Celldex Therapeutics, Inc. returned +83.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Celldex Therapeutics, Inc. do?

Celldex Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted immunotherapies for cancer and other serious diseases.

What is the latest news on CLDX?

The most recent item we track (Zacks Investment Research, 7 Aug 2026): "Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates". Celldex Therapeutics reported a second-quarter loss of $0.94 per share, which was narrower than the Zacks Consensus Estimate of a $1.04 loss but wider than the $0.85 per-share loss from a year ago. The company missed revenue estimates for the quarter.

Company

About Celldex Therapeutics, Inc.

Celldex Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted immunotherapies for cancer and other serious diseases. Its research platforms leverage novel antibody therapeutics, antibody-drug conjugates, and immune-activating agents designed to engage the patient's immune system and deliver precise cytotoxic activity. Key product candidates include barzolvolimab, an investigational monoclonal antibody targeting KIT for chronic spontaneous urticaria and other mast cell-mediated disorders; glembatumumab vedotin, an antibody-drug conjugate against glycoprotein NMB for certain breast and skin cancers; varlilumab, an agonist antibody targeting CD27 to enhance immune responses; CDX-301, a recombinant human Flt3 ligand to expand dendritic and immune cell populations; CDX-1140, an antibody targeting CD40 to activate antigen-presenting cells; and CDX-0159, part of the anti-KIT program. Celldex Therapeutics Inc. advances these programs through clinical trials in oncology, neurology, and inflammatory diseases, primarily serving patients in North America via collaborations with academic centers and industry partners. Founded in 1983 and headquartered in Hampton, New Jersey, it plays a vital role in the biotechnology sector by pioneering next-generation immunotherapies.

CEO Mr. Anthony S. Marucci M.B.A. · 198 employees · United States · https://www.celldex.com